Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations-Reference-Cited by-同舟云学术

Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations

Published:2016-07 Issue: Volume:Volume 10 Page:1205-1215
ISSN:1177-889X
Container-title:Patient Preference and Adherence
language:en
Short-container-title:PPA

Author:

Lee Lulu,Goren Amir,Boytsov Natalie,Donatucci Craig,McVary Kevin

Publisher

Informa UK Limited

Subject

Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Social Sciences (miscellaneous),Medicine (miscellaneous)

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Value of phosphodiesterase 5 inhibitors as a combination therapy for treating erectile dysfunction: A literature review;UroPrecision;2024-03

2. Discontinuation Rates of Tadalafil Alone and in Combination with a-Blockers in the Treatment of Male Lower Urinary Tract Symptoms with or without Coexisting Erectile Dysfunction: A Systematic Review and Meta-Analysis;International Journal of Clinical Practice;2022-11-03

3. Treatment persistence with a fixed-dose combination of tadalafil (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in patients with benign prostatic hyperplasia and erectile dysfunction;Investigative and Clinical Urology;2020

4. Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails;Sexual Medicine Reviews;2019-07

5. Nitric Oxide Synthase in Male Urological and Andrologic Functions;Nitric Oxide Synthase - Simple Enzyme-Complex Roles;2017-05-17